PLANET4Health provides new knowledge and tools on environment degradation and its impact on human animal and ecosystems health. The project results will support policy making process and citizens awareness on sustainable planetary health, climate and environmental policies and adaptation and mitigation strategies to natural hazards. PLANET4health will develop collaborations from a large variety of organizations from the: environmental and climate science, public health, epidemiology, veterinary medicine, social, political and economic science, engineering, law and ethics, and communication, to produce solid knowledge and tools to facilitate learning and practice on the interaction between the natural system and human health. Four tailor-made case studies will be performed: 1) One Health effects of vector-borne diseases, 2) air pollution, 3) food contamination arising from soil and water contamination, 4) mental wellbeing linked to environmental and climate stressors, in different geographical area thanks to the large project network, that will draw universal conclusions and replicable solutions to improve the predictive capability and preparedness. The consortium will produce research, technological innovation, tailored outreach and training, and policy solutions through a cross-sectorial multidisciplinary scientific collaboration in line with the transnational character of planetary health. For these aims the project will: a) collect, organize and assure open availability of new and already existing data on climate and environmental indicators linked to One Health; b) carry out analyses on data and build innovative, inter-operable and multifunctional digital prototypes; c) produce new knowledge and tools to support One Health policies by applying social science theories and involving citizens, policymakers and stakeholders; d) offer open-access data, tools and research material to public authorities for decision making and academic research for further study.

Antimicrobial resistance (AMR) is a global health challenge with an estimated 67% increase in global deaths attributable to AMR by 2050. The European Partnership One Health AMR (EUP OHAMR) is aiming to reduce the burden of AMR with an integrated One Health (OH) approach, recognising that human, animal and plant health are interdependent and interlinked with the environment. The partnership will boost AMR research and innovation (R&I) addressing the current knowledge gaps with the aim to improve surveillance of resistant pathogens and provide better diagnostics and more effective treatments of drug-resistant infections. It will support implementation research on prevention measures reducing the use of antimicrobials and spread of AMR and launch an ambitious work programme of joint activities to coordinate R&I investments, facilitate the use and re-use of R&I data, strengthen AMR R&I capacities and facilitate both knowledge translation and uptake of research results and innovations by industry, society, and policy makers. The EUP OHAMR builds on the long-standing collaboration of the partners from the Joint Programme Initiative on AMR (JPIAMR) but with a bigger ambition and a broader scope. The partnership consists of 53 partners from 30 countries from the European Union (EU) and beyond. With active engagement of key stakeholders across the AMR landscape, the partnership will strengthen European and global synergies through alignment of research priorities, policies, and investments. Furthermore, EUP OHAMR will support multisectoral and multidisciplinary collaborations to break the existing silos in AMR research. It will result in increased knowledge and solutions and provide an evidence base for uptake into policy and practice to prevent and tackle AMR. Thus, the EUP OHAMR will deliver towards to the priorities set in the European One Health Action plan against AMR, thereby strengthening the European Research and Innovation Area ecosystem and contribute to making the EU a best-practice region on AMR.

EP PerMed is a new European Partnership dedicated to Personalised Medicine (PM). It supports PM-related R&I, but also facilitates and accelerates all steps so that PM achievements successfully pass through the full value continuum to be implemented in sustainable health systems for the benefit of people and societies. The partnership will foster demonstration projects and promote successes and lessons learned to demonstrate evidence of PM implementation. EP PerMed activities cover overarching aspects, like patient involvement, exchange with medical societies, infrastructures and international and regional collaboration. The project portfolios of EP PerMed and ERA PerMed (ERA-Net co-fund on PM) and others are supported to become successful innovations in healthcare practice. EP PerMed will be the global PM-platform for scientific and strategic dialogue and alignment, resulting in public documents and publications. Accordingly, it will inform the public, patients, healthcare providers or payers about the latest PM options and engage them. The Strategic Research and Innovation Agenda for Personalised Medicine (SRIA for PM, 2023), developed by EP PerMed partners, is the basis for the partnership's structure and a wide range of its activities. All steps of the SRIA development were strongly support by numerous PM-experts, stakeholders and the European Commission (EC). Thus, the EP PerMed annual Joint Transnational Calls (JTCs) and other funding and activities, events and tools will be in line with the SRIA and outputs will feed into a SRIA update in the coming years. The partnership builds on several developments, initiatives and projects such as ERA PerMed, ICPerMed and its supporting projects (“ICPerMed Family”) funded by the EC. In parallel, it reaches out to the 1+Million Genomes Initiative, other European Partnerships in the Health Cluster and infrastructures like the European Strategy Forum on Research Infrastructures (ESFRI).